Which has preferable valuation & earnings, KZIA or ACXP?

Acurx Pharmaceuticals has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 774.13 -$13.41M N/A N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A

Is KZIA or ACXP more profitable?

Novogen's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Acurx Pharmaceuticals N/A -153.92% -101.69%

Is NEUP or ACXP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Acurx Pharmaceuticals N/A -153.92% -101.69%

Do analysts prefer ACXP or TXMD?

Acurx Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 1,862.03%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ACXP or RKTO?

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A

Is ACXP or RKTO more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Acurx Pharmaceuticals (ACXP) Competitors

$1.58 +0.03 (+1.94%)

As of 11:28 AM Eastern

Compare

ACXP vs. KZIA, AYTU, NEUP, TXMD, and RKTO

Should you buy Acurx Pharmaceuticals stock or one of its competitors? MarketBeat compares Acurx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acurx Pharmaceuticals include Novogen (KZIA), Aytu BioPharma (AYTU), Neuphoria Therapeutics (NEUP), TherapeuticsMD (TXMD), and Rocket One Inc. Common Stock (RKTO). These companies are all part of the "pharmaceutical products" industry.

How does Acurx Pharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	774.13	-$13.41M	N/A	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Novogen currently has a consensus target price of $25.80, indicating a potential upside of 83.30%. Acurx Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 1,862.03%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.9% of Novogen shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Novogen had 1 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 2 mentions for Novogen and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Novogen's score of 1.87 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Very Positive
Acurx Pharmaceuticals	Very Positive

Novogen has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, suggesting that its share price is 309% less volatile than the broader market.

Novogen's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Summary

Novogen beats Acurx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Acurx Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Aytu BioPharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market.

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Aytu BioPharma's score of 1.87 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Very Positive
Acurx Pharmaceuticals	Very Positive

Aytu BioPharma currently has a consensus target price of $10.75, suggesting a potential upside of 399.77%. Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,862.03%. Given Acurx Pharmaceuticals' higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aytu BioPharma and Acurx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neuphoria Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market.

In the previous week, Neuphoria Therapeutics had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Neuphoria Therapeutics' score of 0.57 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Neuphoria Therapeutics	Positive
Acurx Pharmaceuticals	Very Positive

Neuphoria Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 366.15%. Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 1,862.03%. Given Acurx Pharmaceuticals' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuphoria Therapeutics' return on equity of -76.93% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Neuphoria Therapeutics has higher revenue and earnings than Acurx Pharmaceuticals. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.55	-$370K	-$11.06	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Summary

Neuphoria Therapeutics beats Acurx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Acurx Pharmaceuticals (NASDAQ:ACXP) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Acurx Pharmaceuticals has a beta of -2.09, indicating that its share price is 309% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Acurx Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 1,862.03%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a net margin of 5.34% compared to Acurx Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
TherapeuticsMD	5.34%	0.32%	0.23%

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.89 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Very Positive
TherapeuticsMD	Very Positive

TherapeuticsMD has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
TherapeuticsMD	$3.02M	8.51	-$570K	$0.06	37.00

Summary

TherapeuticsMD beats Acurx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Rocket One Inc. Common Stock?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Rocket One Inc. Common Stock's score of 0.94 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acurx Pharmaceuticals	Very Positive
Rocket One Inc. Common Stock	Positive

Acurx Pharmaceuticals has a beta of -2.09, meaning that its share price is 309% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 1,862.03%. Rocket One Inc. Common Stock has a consensus price target of $5.00, indicating a potential upside of 431.86%. Given Acurx Pharmaceuticals' higher possible upside, equities analysts plainly believe Acurx Pharmaceuticals is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Acurx Pharmaceuticals' return on equity of -153.92% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Summary

Acurx Pharmaceuticals beats Rocket One Inc. Common Stock on 8 of the 10 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACXP vs. The Competition

Export

Metric	Acurx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.71M	$3.66B	$6.81B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.39	21.44	27.52	25.33
Price / Sales	N/A	339.00	539.41	102.00
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.76	8.75	10.94	6.61
Net Income	-$7.97M	$23.87M	$3.57B	$336.72M
7 Day Performance	7.48%	3.51%	2.69%	2.63%
1 Month Performance	-18.13%	3.56%	1.84%	0.24%
1 Year Performance	-83.91%	67.21%	36.35%	29.97%

Acurx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACXP Acurx Pharmaceuticals	3.2476 of 5 stars	$1.58 +1.9%	$31.00 +1,862.0%	-84.8%	$6.71M	N/A	N/A	3	Positive News Gap Up
KZIA Novogen	2.8605 of 5 stars	$14.69 +4.9%	$23.75 +61.7%	+124.6%	$24.28M	$42K	N/A	12	Positive News Analyst Forecast Gap Up
AYTU Aytu BioPharma	3.2657 of 5 stars	$2.24 -0.4%	$9.83 +339.0%	-1.4%	$24.04M	$56.60M	N/A	160	Gap Up
NEUP Neuphoria Therapeutics	3.4389 of 5 stars	$4.36 -1.8%	$21.00 +381.7%	-38.5%	$23.54M	$15.65M	N/A	N/A	Short Interest Decrease
TXMD TherapeuticsMD	1.6774 of 5 stars	$2.00 flat	N/A	+90.5%	$23.15M	$3.35M	33.33	420	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACXP) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. KZIA, AYTU, NEUP, TXMD, and RKTO

How does Acurx Pharmaceuticals compare to Novogen?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Acurx Pharmaceuticals compare to Neuphoria Therapeutics?

Summary

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Acurx Pharmaceuticals compare to Rocket One Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. KZIA, AYTU, NEUP, TXMD, and RKTO

How does Acurx Pharmaceuticals compare to Novogen?

Which has preferable valuation & earnings, KZIA or ACXP?

Do analysts rate KZIA or ACXP?

Do insiders and institutionals believe in KZIA or ACXP?

Does the media refer more to KZIA or ACXP?

Which has more volatility and risk, KZIA or ACXP?

Is KZIA or ACXP more profitable?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Do insiders and institutionals have more ownership in AYTU or ACXP?

Which has higher valuation and earnings, AYTU or ACXP?

Is AYTU or ACXP more profitable?

Which has more risk and volatility, AYTU or ACXP?

Does the media refer more to AYTU or ACXP?

Do analysts recommend AYTU or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Neuphoria Therapeutics?

Do insiders and institutionals hold more shares of NEUP or ACXP?

Which has more volatility and risk, NEUP or ACXP?

Does the media favor NEUP or ACXP?

Do analysts rate NEUP or ACXP?

Is NEUP or ACXP more profitable?

Which has better valuation and earnings, NEUP or ACXP?

Summary

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Which has more risk & volatility, ACXP or TXMD?

Do analysts prefer ACXP or TXMD?

Is ACXP or TXMD more profitable?

Do insiders and institutionals have more ownership in ACXP or TXMD?

Does the media refer more to ACXP or TXMD?

Which has stronger earnings and valuation, ACXP or TXMD?

Summary

How does Acurx Pharmaceuticals compare to Rocket One Inc. Common Stock?

Does the media prefer ACXP or RKTO?

Which has more risk & volatility, ACXP or RKTO?

Do analysts recommend ACXP or RKTO?

Which has preferable earnings & valuation, ACXP or RKTO?

Do insiders & institutionals believe in ACXP or RKTO?

Is ACXP or RKTO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools